Jan 08, 2024 / NTS GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everyone. Welcome to the Merck KGaA from Darmstadt, Germany presentation. I've got to get that clear. At the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to welcome the CEO, Belen Garijo, who is going to do the presentation. The Q&A is in this room. So we've got no problems with those logistics. So Belen, welcome to the conference.
Belen Garijo Lopez - Merck KGaA - Chair of Executive Board & CEO
Thank you very much. Thank you, Richard, and good morning, everyone. It's a pleasure to be here one more year, keeping the tradition of starting of the new year with the presentation at JPMorgan. So Happy New Year, everyone. I'm very pleased to be here.
So let me -- next, please. So let me start by stating and even, I would say, celebrating that we have left behind a very tough transition year in 2023. And now we are looking forward to the future with a strong confidence. And why is that? First of all
Merck KGaA at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers